Register Log-in Investor Type

Our Research

RSS Feed
  • 13 Sep2019

    JPMorgan Russian Securities – Outperforming and attractively valued Read More

  • 13 Sep2019

    JPMorgan Russian Securities – Outperforming and attractively valued Read More

  • 12 Sep2019

    Civitas Social Housing – Targeting full dividend cover Read More

  • 12 Sep2019

    Civitas Social Housing – Targeting full dividend cover Read More

  • 12 Sep2019

    Montanaro European Smaller Companies Trust – Focus on the small picture Read More

More Research

Major News Headlines

RSS Feed
Today

QuotedData’s other news 16 September 2019

In QuotedData’s other news 16 September 2019 – GCP Student announced confirmation from FTSE Russell that the company will be added to the FTSE 250 Index from 18 September 2019. AVI Japan Opportunity.released its first interim report since its launch in October 2018. In the few months since launch until the 30 June 2019, its NAV per […]

Today

Adamas Finance Asia updates on its largest holding

Adamas Finance Asia updates on its largest holding – Adamas Finance Asia (ADAM), the pan-Asian diversified investment company, has provided an update on its investment in Future Metal, which was previously known as Hong Kong Mining Holdings. ADAM holds an 85% shareholding in Future Metal, representing ADAM’s largest investment by value in the portfolio. ADAM […]

Today

Custodian REIT pursues disposals to rejig portfolio

Custodian REIT pursues disposals to rejig portfolio – Custodian REIT (CREI), the UK property investment company, has announced the disposal of a property from its portfolio. It has sold a 39,279 sq ft city centre office and retail unit in Edinburgh for £9.1m, in line with the 30 June 2019 valuation, having acquired the property as part of a portfolio in January 2016. CREI says that following the disposal, net gearing has decreased to 21.1%. Commenting on the disposal Richard Shepherd-Cross, managing director […]

13 Sep 2019

Biogen/Eisai discontinue BACE inhibitor in Alzheimer’s 

Biogen/Eisai discontinue BACE inhbitor in Alzheimer’s US-biotech Biogen and its Japanese partner Eisai have stopped two large Phase III studies of the investigational BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat/E2609 for Alzheimer’s disease, after an interim safety review highlighted an unfavourable risk-benefit ratio. The move effectively marks the end of development of agents in this […]

13 Sep 2019

QuotedData’s other news 13 September 2019

In QuotedData’s other news 13 September 2019 – Crystal Amber’s results for the year ended 30 June 2019 show its NAV rising by 1.8% and an NAV total return of 4.1% (including income). The main positive was Leaf Clean Energy (after it won its court case), the detractors were holdings in Northgate and De La Rue. […]

13 Sep 2019

Woodford Patient Capital slashes NAV again

Woodford Patient Capital slashes NAV again – Woodford Patient Capital says it will cut its NAV once again. This time by 4p per share. Bizarrely, the announcement doesn’t tell investors why. The statement says – “Link Fund Solutions Limited (“Link”), through its Fair Value Pricing Committee, is responsible for the valuation of the portfolio of […]

13 Sep 2019

BioPharma lends up to $150m to OptiNose

BioPharma lends up to $150m to OptiNose – BioPharma Credit will lend, alongside BioPharma Credit Investments V, up to $150m via senior secured notes issued by OptiNose US, Inc. BioPharma Credit’s share of the transaction will be up to US$82.5 million and its initial investment US$44.0 million. (BioPharma Credit Investments V (Master) LP is a private fund also […]

12 Sep 2019

Supermarket Income REIT to raise £50m to grow portfolio

Supermarket Income REIT to raise £50m to grow portfolio – Supermarket Income REIT has announced its intention to raise £50m through a share placing and offer to fund new acquisitions. It has set the issue price at 102 pence per new ordinary share, a discount of 5.1% to the closing price of 107.5 pence per existing ordinary share […]

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…